Who is sponsoring SAILS?

SAILS is sponsored by National Heart, Lung, and Blood Institute (NHLBI).

What condition does SAILS study?

SAILS studies Sepsis, Acute Lung Injury.

What drugs are being tested in SAILS?

Interventions: Rosuvastatin, Placebo.

Last reviewed 2016-04-12 · How we verify

Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis (SAILS)

NCT00979121 Phase 3 TERMINATED Results posted

Objective: assess the efficacy and safety of oral rosuvastatin in patients with sepsis-induced Acute Lung Injury (ALI). Hypothesis: Rosuvastatin therapy will improve mortality in patients with sepsis-induced ALI.

Details

Lead sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Phase	Phase 3
Status	TERMINATED
Enrolment	745
Start date	2010-01
Completion	2013-11

Conditions

Sepsis
Acute Lung Injury

Interventions

Rosuvastatin
Placebo

Primary outcomes

Hospital Mortality to Day 60. — 60 days after randomization
The percentage of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.

Countries

United States